114 related articles for article (PubMed ID: 9406713)
1. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma.
DeNardo SJ; Kroger LA; Lamborn KR; Miers LA; O'Donnell RT; Kukis DL; Richman CM; DeNardo GL
Cancer; 1997 Dec; 80(12 Suppl):2583-90. PubMed ID: 9406713
[TBL] [Abstract][Full Text] [Related]
2. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
O'Donnell RT; DeNardo SJ; Miers LA; Lamborn KR; Kukis DL; DeNardo GL; Meyers FJ
Prostate; 2002 Jan; 50(1):27-37. PubMed ID: 11757033
[TBL] [Abstract][Full Text] [Related]
3. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
Denardo SJ; Richman CM; Kukis DL; Shen S; Lamborn KR; Miers LA; Kroger LA; Perez EA; Denardo GL
Anticancer Res; 1998; 18(6A):4011-8. PubMed ID: 9891439
[TBL] [Abstract][Full Text] [Related]
4. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.
DeNardo SJ; Kukis DL; Kroger LA; O'Donnell RT; Lamborn KR; Miers LA; DeNardo DG; Meares CF; DeNardo GL
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):4000-4. PubMed ID: 9108094
[TBL] [Abstract][Full Text] [Related]
5. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
[TBL] [Abstract][Full Text] [Related]
7. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
8. Combined modality radioimmunotherapy. Promise and peril.
Burke PA; DeNardo SJ; Miers LA; Kukis DL; DeNardo GL
Cancer; 2002 Feb; 94(4 Suppl):1320-31. PubMed ID: 11877763
[TBL] [Abstract][Full Text] [Related]
9. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
O'Donnell RT; DeNardo SJ; DeNardo GL; Miers L; Lamborn KR; Kukis DL; Meyers FJ
Prostate; 2000 Aug; 44(3):187-92. PubMed ID: 10906734
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
DeNardo SJ; Zhong GR; Salako Q; Li M; DeNardo GL; Meares CF
J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
DeNardo GL; Kroger LA; Meares CF; Richman CM; Salako Q; Shen S; Lamborn KR; Peterson JJ; Miers LA; Zhong GR; DeNardo SJ
Clin Cancer Res; 1998 Oct; 4(10):2483-90. PubMed ID: 9796981
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
[TBL] [Abstract][Full Text] [Related]
14. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
DeNardo SJ; Gumerlock PH; Winthrop MD; Mack PC; Chi SG; Lamborn KR; Shen S; Miers LA; deVere White RW; DeNardo GL
Cancer Res; 1995 Dec; 55(23 Suppl):5837s-5841s. PubMed ID: 7493356
[TBL] [Abstract][Full Text] [Related]
16. Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
Miers L; Lamborn K; Yuan A; Richman C; Natarajan A; DeNardo S; DeNardo G
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7158s-7163s. PubMed ID: 16203816
[TBL] [Abstract][Full Text] [Related]
17. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
Stein R; Juweid M; Zhang CH; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
Ng B; Kramer E; Liebes L; Wasserheit C; Hochster H; Blank E; Ceriani R; Furmanski P
Cancer Res; 2001 Apr; 61(7):2996-3001. PubMed ID: 11306478
[TBL] [Abstract][Full Text] [Related]
19. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
20. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]